Navigation Links
Genzyme to Build New R&D Center in Beijing
Date:4/22/2008

, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements regarding Genzyme's business plans and strategies, including without limitation: the construction of an R&D facility in Beijing, the incorporation of environmentally sensitive design features and construction techniques into the facility, the commencement of construction of the facility, and the completion and opening of the facility in 2010. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: Genzyme's ability to obtain all required authorizations and permits to build the R&D facility; Genzyme's ability to utilize low impact environmental techniques and to incorporate environmentally sensitive design features into the facility; Genzyme's ability to construct the facility without delays resulting from customary design and construction risks; Genzyme's ability to validate, set-up and commence operations at the facility; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Annual Report on Form 10-K for the period ended December 31, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R), Synvisc(R), Thymoglobulin(R) and Cerezyme(R) are registered trademarks of Genzyme Corporation. All rights reserved.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United St
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genzyme Provides Update on Myozyme(R) Manufacturing
2. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
3. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
4. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
5. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
6. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
7. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
8. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
9. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... element of surprise has been a major advantage of ... Until now, epidemiologists had nothing to measure that might ... suboptimal responses to both the H1N1 pandemic of 2009 ... http://photos.prnewswire.com/prnh/20141121/160242 That virus advantage ... structural changes have been found that invariably to date ...
(Date:11/21/2014)... USA (PRWEB) November 19, 2014 The ... our lives was shared with more than 200 primary ... postgraduate students from the University of Otago Physics Department ... . The Otago students, members of the university’s OSA/SPIE ... Zealand in early September, giving children from small, rural ...
(Date:11/21/2014)... 20, 2014 The report, ... Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, ... Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to ... drivers, threats, opportunities, and challenges. , Browse ... spread through 185 pages and in-depth TOC ...
(Date:11/21/2014)... Dallas, Texas (PRWEB) November 21, 2014 ... China Sodium Ferrocyanide Industry” is a professional and ... it provides Sodium ferrocyanide information, like its ... well as industry overview. This report covers the ... well as global (such as the US, Europe, ...
Breaking Biology Technology:Viruses' Advantage of Surprise is Lost 2Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3
... , NEW YORK and MONTREAL, Dec. 21 /PRNewswire-FirstCall/ ... be targeting U.S. state and municipal regulatory bodies for the ... , "BioSpec Global Solutions will be moving to target regulatory ... " Given the advantages not only on time advantage (10 ...
... , - Company,s results amongst the best for influenza ... /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company ... on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today ... clinical trial with its H5N1 Avian Influenza vaccine candidate ...
... Security personnel need to be able to find explosive ... them. To aid such searches, the National Institute of ... of Homeland Security, has developed a new certified reference ... Compatible with field and laboratory assay methods, the SRM ...
Cached Biology Technology:BioSpec Global Solutions Inc. target market TOGS 9000 to state and municipal regulatory bodies in U.S. market 2Medicago reports positive Phase I results for its avian flu pandemic vaccine 2Medicago reports positive Phase I results for its avian flu pandemic vaccine 3Medicago reports positive Phase I results for its avian flu pandemic vaccine 4New NIST trace explosives standard slated for homeland security duty 2
(Date:11/4/2014)... School of Medicine announced today that it is ... by the Bill & Melinda Gates Foundation. ... and Reproductive Sciences; and Vice Chair of Research ... Medicine will pursue an innovative global health and ... Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds ...
(Date:11/4/2014)... majority of Madagascar,s 101 species of lemurs are threatened ... the rainforests they call home. A new study by ... have on rainforest tree populations, which raises concerns about ... region,s rich biodiversity. , A large proportion of trees ... Lemurs in turn disperse the seeds of their fruit ...
(Date:11/3/2014)...  NeuroSigma ® , Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ... neurological and neuropsychiatric disorders, announced today that the ... Notice of Allowance for Mexican Patent Application No. ... and the Regents of the University of California ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... (BUSM) study shows a mind-body class elective for medical ... thoughts and tasks more effectively. The study, published in ... innovative course may help medical students better manage stress ... their patients. Allison Bond, MA, a third-year medical ...
... drug has shown promise in treating influenza, preventing lung injury ... University of Maryland School of Medicine researchers publishing in the ... that a drug called Eritoran can protect mice from death ... influenza virus. The potential value of this drug as single ...
... of Southampton has investigated public perception of how waste ... opinion of waste management facilities can influence where sites ... Obtaining the support of communities around municipal solid ... successful operation of these services. One common complaint from ...
Cached Biology News:BUSM study shows positive impact of mind-body course on well-being of medical students 2University of Maryland School of Medicine researchers find potential novel treatment for influenza 2Odor and environmental concerns of communities living near waste disposal facilities 2
... described by end-users to be "a delight ... of light microscopy and electronic imaging. With ... does not require much space and can ... environment. The DM-BA300 combines Motic's own revolutionary ...
lid holder -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD69 TAC is designed to deplete human CD69 from samples to isolate resting CD4+ or CD8+ T cells....
... Aquarius 384 is a compact and ... head is a unique flow-through device, ... the included wash system. Optional ... stacker system. Will be upgradable ...
Biology Products: